The stock has been a bit volatile recently and has corrected from the highs. Short-term volatility can be expected for such stocks, and long term prospects depend on the ability of Biozone to deliver on both the fronts, contract manufacturing and QuSomes drug delivery technology. There is another comprehensive review of Biozone on SA which recommends to buy the stock for long term. Dr. Frost owns a significant stake in the company directly and through his companies like Opko Health (OPK). MusclePharm (MSLP) has also invested $2M in Biozone to gain access to QuSomes technology. The $2 million received from MusclePharm is a significant amount considering the cash available with Biozone on June 30.Consequent upon liquidation of Equachem (Biozone's raw material selling business), the net loss has declined by 80%. The R&D spending has increased mainly to further develop the QuSomes. The company may get some pro-rata dividend from liquidation BetaZone Laboratories, a company that engages in the development, sale and licensing of pharmaceuticals and cosmetics in Latin America. Biozone owns 45% in that. Depending upon the exact amount (to be reflected in the earnings), the company's cash position could be strengthened due to the dividend. The possible uses of Qusomes outside the cosmetics market could provide it with huge benefits. The agreement with MusclePharm is also game changing both for the contract manufacturing and the Qusomes technology. MusclePharm is evaluating QuSomes technology and believes QuSomes could improve the absorption and delivery speed of its products It may utilize Biozone's manufacturing facilities for its products. QuSomes can help in reducing cost of manufacture and increase effectiveness at lower dosage. In either case, the pharmaceuticals manufacturers will be excited to embrace the technology once it goes through the usual process of approval etc. The article also mentions some risk factors so needs to read in totality.